Trial reportAntimicrobial agents and chemotherapy2005
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.
Trial report in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.The Journal of antimicrobial chemotherapy · 2017Article
- Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.Antimicrobial agents and chemotherapy · 2014Article
- Candida infections and their prevention.ISRN preventive medicine · 2013Review
- The use of antifungal therapy in neonatal intensive care.Clinics in perinatology · 2012Review
- Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.Antimicrobial agents and chemotherapy · 2011Article
- Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.Antimicrobial agents and chemotherapy · 2011Article
- Current perspectives on echinocandin class drugs.Future microbiology · 2011Review
- FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Antimicrobial agents and chemotherapy · 2011Article
- FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.Antimicrobial agents and chemotherapy · 2010Article
- Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Expert opinion on drug metabolism & toxicology · 2010Review
- Pediatric antifungal agents.Current opinion in infectious diseases · 2009Review
- Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.Antimicrobial agents and chemotherapy · 2009Article
- In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Antimicrobial agents and chemotherapy · 2008Article
- Reverse line blot hybridization assay for identification of medically important fungi from culture and clinical specimens.Journal of clinical microbiology · 2007Article
- Resistance to echinocandin-class antifungal drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2007Review
- Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.Antimicrobial agents and chemotherapy · 2007Article
- Comparison of echinocandin antifungals.Therapeutics and clinical risk management · 2007Article
- Epidemiology of invasive candidiasis: a persistent public health problem.Clinical microbiology reviews · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. The anidulafungin MIC distribution showed that Candida albicans and C. glabrata were the most susceptible species and C. parapsilosis was the least susceptible species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.